It has been reported that GTS-21 has been used in clinical trials to target neuronal α7nAChR in the brain of patients with Alzheimer's disease [47], since the cholinergic anti-inflammatory pathway is activated by stimulating the α7nAChR [33]. This evidence concerns the gene CHRNA7 and early-onset autosomal dominant Alzheimer disease.